Session Details

Imaging is amazing! - All imaging leads to therapy

Fri. Mar 29, 2024 9:45 AM - 11:45 AM JST
Fri. Mar 29, 2024 12:45 AM - 2:45 AM UTC
[Room 301] Conference Center 301 (3F)
Organizer: Yoshinori Kato (Hoshi Univ.), Mikako Ogawa (Dep. Pharm Sci., Hokkaido Univ.)
As the saying goes, "Seeing is believing," information obtained by visualization is beneficial to identifying the location and size of lesions and evaluating the efficacy of treatment. In addition to its benefit in clinical settings, visualization of endogenous and exogenous molecules can lead to the elucidation of biological phenomena in the body and the optimization of treatment/diagnosis in basic and translational research. Various imaging modalities and technologies are used for visualization, and multimodal imaging has significantly contributed to the advancement of medical/pharmaceutical sciences. Imaging modalities or agents can also be applied to therapy directly or indirectly. This symposium will discuss the scientific significance of each imaging technique and address in what way each modality leads to therapy, in particular, frequently-used imaging modalities, "fluorescence," "ultrasound," "nuclear imaging," and "magnetic resonance imaging." As the theme of this symposium indicates, we would like as many meeting participants as possible to attend each presentation and recognize the amazingness of "imaging," knowing that "All imaging leads to therapy."

Opening remarks: Yoshinori Kato (Hoshi Univ.)

[S01-1]Challenges in Imaging and Therapy using light.

○Mikako Ogawa1 (1. Dep. Pharm Sci., Hokkaido Univ.)

[S01-2]Development of novel ultrasound diagnostics and therapeutics by the combination of microbubbles and ultrasound

○Ryo Suzuki1, Kazuo Maruyama1 (1. Fac. Pharma-Sci., Teikyo Univ.)

[S01-3]Development of theranostics probes targeting erythropoietin-producing hepatocellular A2 receptor expressed in cancer

○Hiroyuki Kimura1,2, Kazunori Kato3 (1. Kanazawa Univ., 2. Kyoto Pharm. Univ., 3. Toyo Univ.)

[S01-4]Smart MRI Contrast Agents for Neuroscience and Cancer Research

○Ichio Aoki1 (1. QST)

Discussions

Closing remarks: Mikako Ogawa (Dep. Pharm Sci., Hokkaido Univ.)